IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-35059-x.html
   My bibliography  Save this article

EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis

Author

Listed:
  • Ayushi Verma

    (CSIR-Central Drug Research Institute (CDRI))

  • Akhilesh Singh

    (CSIR-Central Drug Research Institute (CDRI))

  • Manish Pratap Singh

    (CSIR-Central Drug Research Institute (CDRI))

  • Mushtaq Ahmad Nengroo

    (CSIR-Central Drug Research Institute (CDRI))

  • Krishan Kumar Saini

    (CSIR-Central Drug Research Institute (CDRI)
    Academy of Scientific and Innovative Research)

  • Saumya Ranjan Satrusal

    (CSIR-Central Drug Research Institute (CDRI)
    Academy of Scientific and Innovative Research)

  • Muqtada Ali Khan

    (CSIR-Central Drug Research Institute (CDRI))

  • Priyank Chaturvedi

    (CSIR-Central Drug Research Institute (CDRI))

  • Abhipsa Sinha

    (CSIR-Central Drug Research Institute (CDRI))

  • Sanjeev Meena

    (CSIR-Central Drug Research Institute (CDRI))

  • Anup Kumar Singh

    (CSIR-Central Drug Research Institute (CDRI))

  • Dipak Datta

    (CSIR-Central Drug Research Institute (CDRI)
    Academy of Scientific and Innovative Research)

Abstract

Triple-Negative Breast Cancer (TNBC) has a poor prognosis and adverse clinical outcomes among all breast cancer subtypes as there is no available targeted therapy. Overexpression of Enhancer of zeste homolog 2 (EZH2) has been shown to correlate with TNBC’s poor prognosis, but the contribution of EZH2 catalytic (H3K27me3) versus non-catalytic EZH2 (NC-EZH2) function in TNBC progression remains elusive. We reveal that selective hyper-activation of functional EZH2 (H3K27me3) over NC-EZH2 alters TNBC metastatic landscape and fosters its peritoneal metastasis, particularly splenic. Instead of H3K27me3-mediated repression of gene expression; here, it promotes KRT14 transcription by attenuating binding of repressor SP1 to its promoter. Further, KRT14 loss significantly reduces TNBC migration, invasion, and peritoneal metastasis. Consistently, human TNBC metastasis displays positive correlation between H3K27me3 and KRT14 levels. Finally, EZH2 knockdown or H3K27me3 inhibition by EPZ6438 reduces TNBC peritoneal metastasis. Altogether, our preclinical findings suggest a rationale for targeting TNBC with EZH2 inhibitors.

Suggested Citation

  • Ayushi Verma & Akhilesh Singh & Manish Pratap Singh & Mushtaq Ahmad Nengroo & Krishan Kumar Saini & Saumya Ranjan Satrusal & Muqtada Ali Khan & Priyank Chaturvedi & Abhipsa Sinha & Sanjeev Meena & Anu, 2022. "EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis," Nature Communications, Nature, vol. 13(1), pages 1-22, December.
    • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-35059-x
    DOI: 10.1038/s41467-022-35059-x
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-35059-x
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-022-35059-x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. George Papafotiou & Varvara Paraskevopoulou & Eleni Vasilaki & Zoi Kanaki & Nikolaos Paschalidis & Apostolos Klinakis, 2016. "KRT14 marks a subpopulation of bladder basal cells with pivotal role in regeneration and tumorigenesis," Nature Communications, Nature, vol. 7(1), pages 1-11, September.
    2. Talha Anwar & Caroline Arellano-Garcia & James Ropa & Yu-Chih Chen & Hong Sun Kim & Euisik Yoon & Sierrah Grigsby & Venkatesha Basrur & Alexey I. Nesvizhskii & Andrew Muntean & Maria E. Gonzalez & Kel, 2018. "p38-mediated phosphorylation at T367 induces EZH2 cytoplasmic localization to promote breast cancer metastasis," Nature Communications, Nature, vol. 9(1), pages 1-13, December.
    3. Sooryanarayana Varambally & Saravana M. Dhanasekaran & Ming Zhou & Terrence R. Barrette & Chandan Kumar-Sinha & Martin G. Sanda & Debashis Ghosh & Kenneth J. Pienta & Richard G. A. B. Sewalt & Arie P., 2002. "The polycomb group protein EZH2 is involved in progression of prostate cancer," Nature, Nature, vol. 419(6907), pages 624-629, October.
    4. Michael T. McCabe & Heidi M. Ott & Gopinath Ganji & Susan Korenchuk & Christine Thompson & Glenn S. Van Aller & Yan Liu & Alan P. Graves & Anthony Della Pietra III & Elsie Diaz & Louis V. LaFrance & M, 2012. "EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations," Nature, Nature, vol. 492(7427), pages 108-112, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Pauliina M. Munne & Lahja Martikainen & Iiris Räty & Kia Bertula & Nonappa & Janika Ruuska & Hanna Ala-Hongisto & Aino Peura & Babette Hollmann & Lilya Euro & Kerim Yavuz & Linda Patrikainen & Maria S, 2021. "Compressive stress-mediated p38 activation required for ERα + phenotype in breast cancer," Nature Communications, Nature, vol. 12(1), pages 1-17, December.
    2. Shengrui Feng & Sajid A. Marhon & Dustin J. Sokolowski & Alister D’Costa & Fraser Soares & Parinaz Mehdipour & Charles Ishak & Helen Loo Yau & Ilias Ettayebi & Parasvi S. Patel & Raymond Chen & Jiming, 2024. "Inhibiting EZH2 targets atypical teratoid rhabdoid tumor by triggering viral mimicry via both RNA and DNA sensing pathways," Nature Communications, Nature, vol. 15(1), pages 1-18, December.
    3. Jiwei Zhao, 2017. "Reducing bias for maximum approximate conditional likelihood estimator with general missing data mechanism," Journal of Nonparametric Statistics, Taylor & Francis Journals, vol. 29(3), pages 577-593, July.
    4. Julie Rondeaux & Déborah Groussard & Sylvanie Renet & Virginie Tardif & Anaïs Dumesnil & Alphonse Chu & Léa Maria & Théo Lemarcis & Manon Valet & Jean-Paul Henry & Zina Badji & Claire Vézier & Delphin, 2023. "Ezh2 emerges as an epigenetic checkpoint regulator during monocyte differentiation limiting cardiac dysfunction post-MI," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    5. Jiangtao Ren & Zheng Sun & Shuang Zhao & Jinyuan Huang & Yukun Wang & Cheng Zhang & Jinhai Huang & Chenhao Zhang & Ruipu Zhang & Zhihan Zhang & Xu Ji & Zhihui Shao, 2024. "Enantioselective synthesis of chiral α,α-dialkyl indoles and related azoles by cobalt-catalyzed hydroalkylation and regioselectivity switch," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    6. Yatian Li & Zhenyue Gao & Yuhong Wang & Bo Pang & Binbin Zhang & Ruxin Hu & Yuqing Wang & Chao Liu & Xuebin Zhang & Jingxuan Yang & Mei Mei & Yongzhi Wang & Xuan Zhou & Min Li & Yu Ren, 2023. "Lysine methylation promotes NFAT5 activation and determines temozolomide efficacy in glioblastoma," Nature Communications, Nature, vol. 14(1), pages 1-19, December.
    7. Tian Tian & Chunjian Li & Jing Xiao & Yi Shen & Yihua Lu & Liying Jiang & Xun Zhuang & Minjie Chu, 2016. "Quantitative Assessment of the Polymorphisms in the HOTAIR lncRNA and Cancer Risk: A Meta-Analysis of 8 Case-Control Studies," PLOS ONE, Public Library of Science, vol. 11(3), pages 1-11, March.
    8. Xiao Chen & Yinglu Li & Fang Zhu & Xinjing Xu & Brian Estrella & Manuel A. Pazos & John T. McGuire & Dimitris Karagiannis & Varun Sahu & Mustafo Mustafokulov & Claudio Scuoppo & Francisco J. Sánchez-R, 2023. "Context-defined cancer co-dependency mapping identifies a functional interplay between PRC2 and MLL-MEN1 complex in lymphoma," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    9. Tiffany Tate & Tina Xiang & Sarah E. Wobker & Mi Zhou & Xiao Chen & Hyunwoo Kim & Ekatherina Batourina & Chyuan-Sheng Lin & William Y. Kim & Chao Lu & James M. Mckiernan & Cathy Lee Mendelsohn, 2021. "Pparg signaling controls bladder cancer subtype and immune exclusion," Nature Communications, Nature, vol. 12(1), pages 1-14, December.
    10. Sakina A. Plumber & Tiffany Tate & Hikmat Al-Ahmadie & Xiao Chen & Woonyoung Choi & Merve Basar & Chao Lu & Aaron Viny & Ekatherina Batourina & Jiaqi Li & Kristjan Gretarsson & Besmira Alija & Andrei , 2024. "Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer," Nature Communications, Nature, vol. 15(1), pages 1-16, December.
    11. Varadha Balaji Venkadakrishnan & Adam G. Presser & Richa Singh & Matthew A. Booker & Nicole A. Traphagen & Kenny Weng & Nathaniel C. E. Voss & Navin R. Mahadevan & Kei Mizuno & Loredana Puca & Osasena, 2024. "Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes," Nature Communications, Nature, vol. 15(1), pages 1-15, December.
    12. Lin Zhang & Jingkun Qu & Yutao Qi & Yimin Duan & Yu-Wen Huang & Zhifen Zhou & Ping Li & Jun Yao & Beibei Huang & Shuxing Zhang & Dihua Yu, 2022. "EZH2 engages TGFβ signaling to promote breast cancer bone metastasis via integrin β1-FAK activation," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    13. Debashis Ghosh & Arul Chinnaiyan, 2004. "Covariate adjustment in the analysis of microarray data from clinical studies," The University of Michigan Department of Biostatistics Working Paper Series 1030, Berkeley Electronic Press.
    14. Antonio Rodriguez-Calero & John Gallon & Dilara Akhoundova & Sina Maletti & Alison Ferguson & Joanna Cyrta & Ursula Amstutz & Andrea Garofoli & Viola Paradiso & Scott A. Tomlins & Ekkehard Hewer & Ver, 2022. "Alterations in homologous recombination repair genes in prostate cancer brain metastases," Nature Communications, Nature, vol. 13(1), pages 1-10, December.
    15. Wen Hao Neo & Yiran Meng & Alba Rodriguez-Meira & Muhammad Z. H. Fadlullah & Christopher A. G. Booth & Emanuele Azzoni & Supat Thongjuea & Marella F. T. R. Bruijn & Sten Eirik W. Jacobsen & Adam J. Me, 2021. "Ezh2 is essential for the generation of functional yolk sac derived erythro-myeloid progenitors," Nature Communications, Nature, vol. 12(1), pages 1-12, December.
    16. Carolina Gracia-Diaz & Yijing Zhou & Qian Yang & Reza Maroofian & Paula Espana-Bonilla & Chul-Hwan Lee & Shuo Zhang & Natàlia Padilla & Raquel Fueyo & Elisa A. Waxman & Sunyimeng Lei & Garrett Otrimsk, 2023. "Gain and loss of function variants in EZH1 disrupt neurogenesis and cause dominant and recessive neurodevelopmental disorders," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
    17. Brajendra K. Tripathi & Meghan F. Anderman & Disha Bhargava & Luciarita Boccuzzi & Xiaolan Qian & Dunrui Wang & Marian E. Durkin & Alex G. Papageorge & Fernando J. Miguel & Katerina Politi & Kylie J. , 2021. "Inhibition of cytoplasmic EZH2 induces antitumor activity through stabilization of the DLC1 tumor suppressor protein," Nature Communications, Nature, vol. 12(1), pages 1-15, December.
    18. Marco Bolis & Daniela Bossi & Arianna Vallerga & Valentina Ceserani & Manuela Cavalli & Daniela Impellizzieri & Laura Di Rito & Eugenio Zoni & Simone Mosole & Angela Rita Elia & Andrea Rinaldi & Ricar, 2021. "Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression," Nature Communications, Nature, vol. 12(1), pages 1-15, December.
    19. Nikhil B. Ghate & Sungmin Kim & Yonghwan Shin & Jinman Kim & Michael Doche & Scott Valena & Alan Situ & Sangnam Kim & Suhn K. Rhie & Heinz-Josef Lenz & Tobias S. Ulmer & Shannon M. Mumenthaler & Wooji, 2023. "Phosphorylation and stabilization of EZH2 by DCAF1/VprBP trigger aberrant gene silencing in colon cancer," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    20. Nishit Goradia & Stefan Werner & Edukondalu Mullapudi & Sarah Greimeier & Lina Bergmann & Andras Lang & Haydyn Mertens & Aleksandra Węglarz & Simon Sander & Grzegorz Chojnowski & Harriet Wikman & Oliv, 2024. "Master corepressor inactivation through multivalent SLiM-induced polymerization mediated by the oncogene suppressor RAI2," Nature Communications, Nature, vol. 15(1), pages 1-16, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-35059-x. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.